Omega Active PRM (60 caps)
Omega Active PRM (60 caps)
100% Guarantee
Dr. Shippy Approved
Metabolites of PRMs, known as specialized PRMs, provide building blocks to support the natural resolution of the immune response.*
Pro-resolving mediators (PRMs) are metabolites of omega-3 and omega-6 fatty acids. The most abundant PRMs are 14-HDHA, 17-HDHA, and 18-HEPE.
These PRMs are further metabolized to naturally occurring signaling molecules referred to as specialized PRMs (SPMs).
The function of SPMs is to downregulate the inflammatory process after the initial immune response, allowing a return to homeostasis.
Also known as “resolving agonists,” SPMs target specific immune cells to switch off, or resolve, the inflammatory response that naturally occurs with acute injury or illness.
Without a resolution, inflammation may linger after the acute phase has passed, leading to an increased risk for significant chronic health issues.*
Essential fatty acids are released from circulation to provide the substrate for forming SPMs. The positive benefits of omega-3s for many clinical indications may be attributed to the action of SPMs.
Directions: Take two capsules daily, or as directed by your healthcare professional. Consult your healthcare professional prior to use. Individuals taking medication should discuss potential interactions with their healthcare professional. Do not use if tamper seal is damaged.
Contains: Fish (anchovy, sardine, herring, and mackerel) and squid.
Formulated to Exclude: Wheat, gluten, corn, yeast, soy, dairy products, crustacean shellfish, peanuts, tree nuts, egg, sesame, ingredients derived from genetically modified organisms (GMOs), artificial colors, and artificial sweeteners.
References
1. Serhan CN. Nature. 2014;510(7503):92-101. doi:10.1038/nature13479
2. Hansen TV, Vik A, Serhan CN. Front Pharmacol. 2019;9:1582. doi:10.3389/fphar.2018.01582
3. Norling LV, Ly L, Dalli J. Curr Opin Clin Nutr Metab Care. 2017;20(2):145-152. doi:10.1097/MCO.0000000000000353
4. Neuhofer A, Zeyda M, Mascher D, et al. Diabetes. 2013;62(6):1945-1956. doi:10.2337/db12-0828
5. Bannenberg G, Serhan CN. Biochim Biophys Acta. 2010;1801(12):1260-1273. doi:10.1016/j.bbalip.2010.08.002
6. Dalli J, Serhan CN. Curr Opin Immunol. 2018;50:48-54. doi:10.1016/j.coi.2017.10.007
7. So J, Wu D, Lichtenstein AH, et al. Atherosclerosis. 2021;316:90-98. doi:10.1016/j.atherosclerosis.2020.11.018
8. Kain V, Ingle KA, Colas RA, et al. J Mol Cell Cardiol. 2015;84:24-35. doi:10.1016/j.yjmcc.2015.04.003
9. Clària J, González-Périz A, López-Vicario C, et al. Front Immunol. 2011;2:49. doi:10.3389/fimmu.2011.00049
10. López-Vicario C, Titos E, Walker ME, et al. FASEB J. 2019;33(6):7072-7083. doi:10.1096/fj.201802587R